We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. By clicking “Accept,” you agree to our website's cookie use as described in our Cookie Policy. You can change your cookie settings at any time by clicking “Preferences.”
About

Market Analysis

65%
F&G: 34
EARLY RECOVERYYield: 0.65%
Summing up, today’s market action continues to revolve around familiar forces: earnings revisions and guidance, the evolving path of interest rates and inflation, and a tug-of-war between mega-cap growth leadership and broader market participation.[3][4] Even without citing individual live price moves, the underlying message for investors is consistent: focus on balance-sheet strength, cash-flow durability, and sensible diversification rather than trying to predict every intraday swing. By combining a quality-focused core, a thoughtful barbell between growth and value, and stabilizing income and defensive exposures, portfolios can remain resilient across a wide range of possible macro and market outcomes.

Market Pulse

65% advancingEARLY RECOVERY phase
advertising 2.40%, franchise 2.32%contract -0.60%

Fear & Greed

34fear

Outlook

Synchronized Growth 30%Inflationary Boom 25%Global Recession 20%

Sectors

Materials 1.08%Other -0.23%, Utilities -0.18%

Bonds

3M:3.80%10Y:4.45%
Slope:0.65%(normal)

News

Lundbeck drug candidate shows promise in Cushing's disease trial
Lundbeck drug candidate shows promise in Cushing's disease trial
📊Thesis Ideas Based on Market Conditions
🏦 Fed Easing and Curve Steepening Shift Flows From Cash to Duration Assets
📈 AI Industrialization Drives Capex to Chips and Power While Squeezing SaaS Margins
🌍 Geopolitical Fragmentation and Security Focus Channel Capital to Defense and Away From Discretionary
🔄 Valuation Strain and Dispersion Fuel Rotation From Mega-Cap AI Into Cyclicals and Small-Cap Value
📉 Softening Dollar and Policy Divergence Spur Rotation Into EM and Asia Tech at Expense of US Multinationals
📈 Healthcare and Biopharma Attract Defensive and Innovation Capital Amid Rich Market Valuations
🏦 Fed Easing and Curve Steepening Shift Flows From Cash to Duration Assets
📈 AI Industrialization Drives Capex to Chips and Power While Squeezing SaaS Margins
🌍 Geopolitical Fragmentation and Security Focus Channel Capital to Defense and Away From Discretionary
🔄 Valuation Strain and Dispersion Fuel Rotation From Mega-Cap AI Into Cyclicals and Small-Cap Value
📉 Softening Dollar and Policy Divergence Spur Rotation Into EM and Asia Tech at Expense of US Multinationals
📈 Healthcare and Biopharma Attract Defensive and Innovation Capital Amid Rich Market Valuations
Date
Company
Employee Outlook
Market Cap
Growth
Short %
Signals
Analysts Rating
Industry
Economic Events:
Sentiment:10%
Money market funds, short-duration equities, and floating-rate bond beneficiaries losing carry advantage as Fed rate-cut cycle compresses yield advantage; capital reallocates to longer-duration and income-generating alternatives.+0.0%6↑ / 2↓     
Aug 10
Estimated earnings date57 days
I
Invesco Ultra Short Duration ET (GSY)
N/A
ETF
Aug 10
Estimated earnings date57 days
V
Vanguard Ultra-Short Bond ETF (VUSB)
N/A
ETF
Aug 10
Estimated earnings date57 days
S
SPDR Bloomberg 1-3 Month T-Bill (BIL)
N/A
ETF
Aug 10
Estimated earnings date57 days
i
iShares 0-3 Month Treasury Bond (SGOV)
N/A
ETF
Aug 10
Estimated earnings date57 days
F
Fidelity Government Money Marke (SPAXX)
N/A
-0.10 +0%N/A
Aug 10
Estimated earnings date57 days
V
Vanguard Money Market Reserves (VMFXX)
N/A
ETF
Aug 10
Estimated earnings date57 days
V
Vanguard Intermediate-Term Trea (VGIT)
N/A
ETF
Aug 10
Estimated earnings date57 days
V
Vanguard Short-Term Bond ETF (BSV)
N/A
0.61ETF
Aug 10
Estimated earnings date57 days
i
iShares Short Treasury Bond ETF (SHV)
N/A
ETF
Sep 2
Estimated earnings date80 days
V
Vanguard Short-Term Bond Index (VBIRX)
N/A
0.61N/A